Gemini Bio to Distribute Scinus Products in the U.S.

Gemini Bioproducts, LLC, a supplier of cell culture solutions and a portfolio company of BelHealth Investment Partners, LLC, a New York-based healthcare private equity firm, has entered a distribution agreement with Scinus Cell Expansion Netherlands BV. Customers will now be able to purchase the Scinus Cell expansion bioreactor system directly from Gemini Bio in the U.S.
 
This cell expansion bioreactor system enables clinical scale stem cell cultivation in a controlled environment, which is a cost-effective alternative to traditional 2D cell growth in tissue culture flasks or cell stacks. The system contains a single use bioreactor bag that can be used to cultivate cells to clinically relevant numbers, which can enable cutting edge cell therapies to be delivered to patients.
 
“I am extremely excited to add Scinus’ innovative Bioreactor to the Gemini portfolio,” said Brendan Lucey, vice president of business development, Gemini Bio. “In addition to supplying reagents and instruments for cell quality control, we now have a next generation bioreactor for cell therapy applications. This addition continues our focus on supporting breakthroughs in the cell therapy field with innovative bioprocessing solutions that allow for an easy transition from R&D to clinical manufacturing.”
 
Michiel Jannink, chief executive officer, Scinus Cell Expansion, said, “We are really looking forward to working with Gemini Bio. Our products are very complementary and we both have the same mission: to bring the field of cell therapy further.”

To watch a video and learn more about the Scinus Cell Expansion Bioreactor, click here.